PL3730136T3 - Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek - Google Patents

Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek

Info

Publication number
PL3730136T3
PL3730136T3 PL20163104.1T PL20163104T PL3730136T3 PL 3730136 T3 PL3730136 T3 PL 3730136T3 PL 20163104 T PL20163104 T PL 20163104T PL 3730136 T3 PL3730136 T3 PL 3730136T3
Authority
PL
Poland
Prior art keywords
treatment
kidney disease
chronic kidney
disease patients
ferric citrate
Prior art date
Application number
PL20163104.1T
Other languages
English (en)
Polish (pl)
Inventor
Enrique Poradosu
Ron BENTSUR
James F. OLIVIERO III
Original Assignee
Keryx Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals, Inc. filed Critical Keryx Biopharmaceuticals, Inc.
Publication of PL3730136T3 publication Critical patent/PL3730136T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20163104.1T 2012-06-21 2013-06-21 Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek PL3730136T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PL3730136T3 true PL3730136T3 (pl) 2024-03-25

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20163104.1T PL3730136T3 (pl) 2012-06-21 2013-06-21 Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek

Country Status (19)

Country Link
US (3) US20130345303A1 (enExample)
EP (3) EP4335436A3 (enExample)
JP (4) JP2015535209A (enExample)
KR (2) KR20200103855A (enExample)
CN (2) CN113244209A (enExample)
AU (2) AU2013278000A1 (enExample)
BR (1) BR112014032049A2 (enExample)
CA (1) CA2876982A1 (enExample)
DK (1) DK3730136T3 (enExample)
EA (1) EA201590062A1 (enExample)
ES (2) ES2796254T3 (enExample)
FR (1) FR25C1043I1 (enExample)
HK (1) HK1214503A1 (enExample)
IL (1) IL236356A0 (enExample)
MX (1) MX2014015615A (enExample)
NO (1) NO2025048I1 (enExample)
PL (1) PL3730136T3 (enExample)
SG (2) SG11201408521WA (enExample)
WO (1) WO2013192565A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
CN105873583A (zh) * 2013-11-04 2016-08-17 凯克斯生物制药公司 用于降低慢性肾病患者的心力衰竭的枸橼酸铁
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
CN107530310A (zh) * 2015-03-04 2018-01-02 凯克斯生物制药公司 柠檬酸铁在治疗缺铁性贫血中的用途
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US20210085711A1 (en) 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230118A (zh) * 1996-07-19 1999-09-29 日研化学株式会社 高磷血症治疗剂
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
WO2007081744A2 (en) * 2006-01-06 2007-07-19 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP1978808B1 (en) * 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태

Also Published As

Publication number Publication date
DK3730136T3 (da) 2024-01-22
HK1210013A1 (en) 2016-04-15
CN113244209A (zh) 2021-08-13
MX2014015615A (es) 2015-03-20
EP2863906B1 (en) 2020-03-18
AU2013278000A1 (en) 2015-01-22
US20150079168A1 (en) 2015-03-19
EP3730136A1 (en) 2020-10-28
JP2015535209A (ja) 2015-12-10
SG10201805177PA (en) 2018-07-30
US20140234416A1 (en) 2014-08-21
WO2013192565A2 (en) 2013-12-27
FR25C1043I1 (fr) 2026-01-02
EP2863906A2 (en) 2015-04-29
KR102150135B1 (ko) 2020-08-31
WO2013192565A3 (en) 2015-10-15
AU2018203205A1 (en) 2018-05-31
JP2022070945A (ja) 2022-05-13
HK1214503A1 (zh) 2016-07-29
JP2018138562A (ja) 2018-09-06
CN104884055A (zh) 2015-09-02
EP4335436A2 (en) 2024-03-13
BR112014032049A2 (pt) 2017-07-25
JP2020100638A (ja) 2020-07-02
US20130345303A1 (en) 2013-12-26
EA201590062A1 (ru) 2016-02-29
ES2796254T3 (es) 2020-11-26
AU2018203205B2 (en) 2020-03-12
IL236356A0 (en) 2015-02-26
NO2025048I1 (no) 2025-11-06
KR20200103855A (ko) 2020-09-02
KR20150036131A (ko) 2015-04-07
EP3730136B1 (en) 2023-12-27
CA2876982A1 (en) 2013-12-27
EP4335436A3 (en) 2024-05-15
ES2970050T3 (es) 2024-05-24
SG11201408521WA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
IL236356A0 (en) Use of iron citrate to treat patients with chronic kidney disease
IL260579B (en) Diagnosis, prevention and treatment of joint diseases
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL239007A0 (en) Use of Aribolin to treat breast cancer
GB201314512D0 (en) Dual Haemodialysis and Haemodiafiltration blood treatment device
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
EP2875158A4 (en) USE OF MICROVESICLES IN THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES AND MEDICAL SUDDEN
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
SG11201603091QA (en) Ferric citrate for reducing cardiac failure in chronic kidney disease patients
HUE053156T2 (hu) Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél
IL237765B (en) Treatment of vascular disease and its complications
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
GB201207543D0 (en) Treatment of transfusion blood
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
SG11201601490XA (en) Risk markers for cardiovascular disease in patients with chronic kidney disease
ZA201404000B (en) Fluid-injection system for medical use in the vascular system of a patient
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
HUE039153T2 (hu) Kompozíciók diszlipidémia kezelésében való alkalmazásra krónikus vesebetegségnél
PL2702033T3 (pl) Zastosowanie soli 3-karboksy-N-etylo-N,N-dimetylopropano-1-amoniowych do leczenia choroby układu krążenia
PL2928461T3 (pl) Leczenie przewlekłej choroby nerek
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease